Pizzuti Dana's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Aug 26, 2025
- Accession no.
- 0001948238-25-000007
- Filed
- Aug 26, 2025
- Trade date
- Aug 22, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $912.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pizzuti DanaCIK 0001948238 | Officer (Chief Med and Dev Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | Common Stock | MOption exerciseAcquired | +30,000 | $16.89 | +$506,700 | 96,270 | Direct | |
| Aug 22, 2025 | Common Stock | SSaleDisposed | −30,000 | $30.43F2 | −$912,900 | 66,270 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 89,042 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.